Government allocates Remdesivir supply to 19 States/UTs with rising Covid cases

Our Bureau New Delhi | Updated on April 21, 2021

Import duty on Remdesivir API, injections waived   -  Kunal Mahto

Export of Remdesivir has also been prohibited in order to shore up domestic supplies

With the rise in Covid patients, demand for Remdisivir injection has also gone up, and to meet that the government has made an interim allocation of the anti viral drug for 19 States/UTs for the period up to April 30, 2021. These 19 states are Chhattisgarh, Delhi, Gujarat, Haryana, Andhra Pradesh, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Punjab, Rajasthan, Tamil Nadu, Uttar Pradesh, Uttarakhand, Telangana, West Bengal, Odisha, Bihar and Jharkhand.

“Remdesivir being an investigational therapy drug given in acute and severe versions of Covid-19 where oxygen support is a must, this allocation pertains to 14 States to which medical oxygen is allocated and 5 other states where the high volume of supplies are being observed,” the Union Health Ministry said on Wednesday in a statement.

The allocation includes bulk purchases made by the states as well as supplies through private distribution channels. This initial allocation is dynamic and will be reviewed constantly in consultation with the states, to ensure all needs can be met within the available supplies, the ministry added.

Keeping in mind the sudden surge in demand in the country for Remdesivir Injection required for Covid-19 therapy, the manufacturing capacity of domestic Remdesivir manufacturers has been ramped up. The production capacity is being ramped up from current level of 38 lakh vials per month to 74 lakh vials per month, and 20 additional manufacturing sites have been approved. Export of Remdesivir has also been prohibited on April 11, 2021 in order to shore up domestic supplies, as per the government release. Customs duty has also been waived for imports of Remdesivir API, injections.

Published on April 21, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.